Bhumsuk Keam1,2, Sung-Bae Kim3, Seong Hoon Shin4, Byoung Chul Cho5, Keun-Wook Lee6, Min Kyoung Kim7, Hwan-Jung Yun8, Se-Hoon Lee1,2, Dok Hyun Yoon3, Yung-Jue Bang1,2. 1. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea. 2. Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 3. Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. 4. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea. 5. Department of Internal Medicine, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Republic of Korea. 6. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea. 7. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea. 8. Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea.
Abstract
BACKGROUND: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS: ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until disease progression or unacceptable toxicities. The primary endpoint was the probability of 4-month progression-free survival (PFS). Metabolic response was evaluated with positron emission tomography (PET)/computed tomography (CT) scans performed at the baseline and after 8 weeks of treatment. RESULTS: Between September 2011 and April 2013, 32 patients with metastatic and/or unresectable ACC were enrolled in this prospective, multicenter trial. The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%. Among 26 patients with PET/CT scans both before and after treatment (at 8 weeks), the metabolic activity of ACC was reduced in 13 patients (50.0%), and 5 patients (19.2%) achieved a metabolic partial response, which was defined as a ≥25% reduction in maximum standardized uptake values. Common grade 3 and 4 adverse events were asthenia (50.0%) and neutropenia (25.0%). CONCLUSIONS: Dovitinib shows modest antitumor activity in the treatment of ACC.
BACKGROUND: The objective of this study was to evaluate the efficacy and safety of dovitinib in patients with adenoid cystic carcinoma (ACC). METHODS: ACC patients with documented disease progression within the past 12 months were eligible. Patients received oral dovitinib (500 mg once daily for 5 consecutive days followed by a 2-day rest every week) until disease progression or unacceptable toxicities. The primary endpoint was the probability of 4-month progression-free survival (PFS). Metabolic response was evaluated with positron emission tomography (PET)/computed tomography (CT) scans performed at the baseline and after 8 weeks of treatment. RESULTS: Between September 2011 and April 2013, 32 patients with metastatic and/or unresectable ACC were enrolled in this prospective, multicenter trial. The 4-month PFS probability was 80.4%, and the median PFS was 6.0 months (95% confidence interval, 4.4-7.6 months). Tumor shrinkage was observed in 22 patients (68.8%), and 1 patient had a confirmed partial response. The disease control rate was 96.9%. Among 26 patients with PET/CT scans both before and after treatment (at 8 weeks), the metabolic activity of ACC was reduced in 13 patients (50.0%), and 5 patients (19.2%) achieved a metabolic partial response, which was defined as a ≥25% reduction in maximum standardized uptake values. Common grade 3 and 4 adverse events were asthenia (50.0%) and neutropenia (25.0%). CONCLUSIONS:Dovitinib shows modest antitumor activity in the treatment of ACC.
Authors: Vatche Tchekmedyian; Eric J Sherman; Lara Dunn; Crystal Tran; Shrujal Baxi; Nora Katabi; Cristina R Antonescu; Irina Ostrovnaya; Sofia S Haque; David G Pfister; Alan L Ho Journal: J Clin Oncol Date: 2019-04-02 Impact factor: 44.544
Authors: Prashanth J Prabakaran; Amal M Javaid; Adam D Swick; Lauryn R Werner; Kwangok P Nickel; Emmanuel Sampene; Rong Hu; Irene M Ong; Justine Y Bruce; Gregory K Hartig; Aaron M Wieland; Jude Canon; Paul M Harari; Randall J Kimple Journal: Clin Cancer Res Date: 2017-06-28 Impact factor: 12.531
Authors: Patrick M Dillon; Gina R Petroni; Bethany J Horton; Christopher A Moskaluk; Paula M Fracasso; Michael G Douvas; Nikole Varhegyi; Snjezana Zaja-Milatovic; Christopher Y Thomas Journal: Clin Cancer Res Date: 2017-04-04 Impact factor: 12.531
Authors: Sarah Atallah; Morgane Marc; Antoine Schernberg; Florence Huguet; Isabelle Wagner; Antti Mäkitie; Bertrand Baujat Journal: Cancer Manag Res Date: 2022-06-04 Impact factor: 3.602
Authors: A L Ho; L Dunn; E J Sherman; M G Fury; S S Baxi; R Chandramohan; S Dogan; L G T Morris; G D Cullen; S Haque; C S Sima; A Ni; C R Antonescu; N Katabi; D G Pfister Journal: Ann Oncol Date: 2016-08-26 Impact factor: 32.976
Authors: Haitham AlRabiah; Adnan A Kadi; Haya I Aljohar; Mohamed W Attwa; Nasser S Al-Shakliah; Sabry M Attia; Gamal Ae Mostafa Journal: Drug Des Devel Ther Date: 2020-01-28 Impact factor: 4.162